The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer.

Seo, S; Woo, C G; Lee, D H; Choi, J

Seo, S; Woo, C G; Lee, D H; Choi, J.

Afiliación

Seo S; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul.
Woo CG; Department of Pathology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju.
Lee DH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul.
Choi J; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Ann Oncol ; 28(7): 1667-1668, 2017 07 01.

Article en En | MEDLINE | ID: mdl-28407036

Asunto(s)

Carcinoma de Pulmón de Células no Pequeñas; Neoplasias Pulmonares; Crizotinib; Humanos; Proteínas de Fusión Oncogénica; Inhibidores de Proteínas Quinasas; Pirazoles; Piridinas; Proteínas Tirosina Quinasas Receptoras

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google